Osteoporosis a disease characterized by decreased bone mineral density (BMD), which causes brittle bones and increases the risk of fracture. The disease affects 10 million Americans, with 34 million more estimated to have a low bone mass and increased risk of the disease. Since bone mineral density naturally decreases with age, osteoporosis most commonly affects those over 50. As the baby boomer generation ages and people continue to live longer, the incidence of osteoporosis is expected to increase.
In women over 45, osteoporosis is responsible for more hospital stays than many other diseases such as diabetes, heart attack, or breast cancer.. An estimated $18 billion is spent annually on direct health care services related to osteoporotic fractures, making it an attractive market for pharmaceutical companies that produce drugs to help manage the disease.
According to a new report published by Transparency Market Research “Osteoporosis Drug Market- Global and China market analysis, size, trends and forecast (2010-2015)“ (http://www.transparencymarketresearch.com/osteoporosis-drug-market.html) Global Osteoporosis Market is estimated to be USD 7.3 billion in 2010 and expected to reach USD 11.4 billion in 2015 at a CAGR of 9.2% over the period 2010 to 2015. Bisphosphonate segment accounted for the largest share at 62.0% of weight management market in 2010. China Osteoporosis market will be worth USD 2.5 billion in 2015.
The osteoporosis market is currently $7 billion and is projected to reach $10.4 billion by 2011.  Some major players are:
Health insurance companies such as Aetna (AET), UnitedHealth Group (UNH), WellPoint Health Networks (WLP), and AFLAC (AFL) may be hurt by the increased incidence of osteoporosis because reimbursement costs will increase.
Medicare, which covers most health costs for those over 65, has a particularly large impact on the osteoporosis market due to the overlapping demographics of the patient population. While Medicare currently covers most osteoporosis treatments, changes in osteoporosis coverage will affect both pharmaceutical and health insurance companies.
Osteoporosis is caused by decreased bone mineral density (BMD), and leads to brittle bones and increased the risk of fracture. The condition is defined in medicine as having a BMD of 2.5 standard deviations below a person's expected peak bone mass. Osteoporosis affects 10 million Americans, with 34 million more estimated to have a low bone mass and increased risk of the disease.
6. http://www.transparencymarketresearch.com/osteoporosis-drug-market.html Osteoporosis Drug Market